Evelo Biosciences

    OverviewSuggest Edit

    Evelo Biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines. The Company is harnessing the therapeutic potential of specific strains of naturally occurring microbes and developing them as a new class of medicines, monoclonal microbials. Evelo has validated that orally delivered monoclonal microbials modulate immunological and biological effects throughout the body after initial interactions with human cells in the gut. The Company is pioneering the development of this new class of medicine for the treatment of autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer.

    TypePublic
    Founded2015
    HQCambridge, MA, US
    Websiteevelobio.com

    Latest Updates

    Employees (est.) (Feb 2019)56
    Cybersecurity ratingAMore

    Evelo Biosciences Office Locations

    Evelo Biosciences has an office in Cambridge
    Cambridge, MA, US (HQ)
    620 Memorial Dr
    Show all (1)

    Evelo Biosciences Financials and Metrics

    Evelo Biosciences Revenue

    USD

    Net income (FY, 2017)

    (28.0m)

    EBIT (FY, 2017)

    (27.5m)

    Cash (31-Dec-2017)

    38.2m
    USDFY, 2016FY, 2017

    General and administrative expense

    3.9m7.6m

    R&D expense

    9.1m20.0m

    Operating expense total

    13.0m27.5m

    EBIT

    (13.0m)(27.5m)
    USDFY, 2016FY, 2017

    Cash

    15.5m38.2m

    Prepaid Expenses

    184.0k531.0k

    Current Assets

    15.7m38.8m

    PP&E

    2.5m3.5m
    USDFY, 2016FY, 2017

    Net Income

    (13.3m)(28.0m)

    Depreciation and Amortization

    419.0k1.5m

    Accounts Payable

    273.0k1.7m

    Cash From Operating Activities

    (12.3m)(23.3m)
    USDFY, 2016

    Debt/Equity

    -0.4 x

    Debt/Assets

    0.5 x

    Financial Leverage

    -0.7 x
    Show all financial metrics

    Evelo Biosciences Operating Metrics

    Apr, 2018

    Patent Applications

    67

    Patents Issued

    7

    Pre-Clinical Phase Products

    3
    Show all operating metrics

    Evelo Biosciences Acquisitions / Subsidiaries

    Company NameDateDeal Size
    Evelo Biosciences Security Corporation

    Evelo Biosciences Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    92/100

    SecurityScorecard logo

    Evelo Biosciences Environment, Social & Governance (ESG) Ratings

    CSRHub ESG ratingPremium dataset

    40-49

    out of 100

    CSRHub logo

    Evelo Biosciences Online and Social Media Presence

    Embed Graph

    Evelo Biosciences News and Updates

    Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team

    CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion o…

    Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer

    CAMBRIDGE, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Mark Plinio as Chief Commercial Officer, effective June 14, 2021. Mr. Plinio…

    Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights

    –Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors––Announced strategic collaboration with Ab…

    Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021

    CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to …

    Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis

    –Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting–
    Show more

    Evelo Biosciences Frequently Asked Questions

    • When was Evelo Biosciences founded?

      Evelo Biosciences was founded in 2015.

    • How many employees does Evelo Biosciences have?

      Evelo Biosciences has 56 employees.

    • Who are Evelo Biosciences competitors?

      Competitors of Evelo Biosciences include Biocon, Livzon Pharmaceutical Group and Genentech.

    • Where is Evelo Biosciences headquarters?

      Evelo Biosciences headquarters is located at 620 Memorial Dr, Cambridge.

    • Where are Evelo Biosciences offices?

      Evelo Biosciences has an office in Cambridge.

    • How many offices does Evelo Biosciences have?

      Evelo Biosciences has 1 office.